vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Orion Properties Inc. (ONL). Click either name above to swap in a different company.
Orion Properties Inc. is the larger business by last-quarter revenue ($36.3M vs $21.2M, roughly 1.7× Autolus Therapeutics plc). Orion Properties Inc. runs the higher net margin — -37.4% vs -373.3%, a 335.9% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
AUTL vs ONL — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $36.3M |
| Net Profit | $-79.1M | $-13.6M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | -9.3% |
| Net Margin | -373.3% | -37.4% |
| Revenue YoY | — | -4.6% |
| Net Profit YoY | 3.6% | -45.0% |
| EPS (diluted) | $-0.30 | $-0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $36.3M | ||
| Q4 25 | — | $35.2M | ||
| Q3 25 | $21.2M | $37.1M | ||
| Q2 25 | $20.9M | $37.3M | ||
| Q1 25 | $9.0M | $38.0M | ||
| Q4 24 | — | $38.4M | ||
| Q3 24 | $0 | $39.2M | ||
| Q2 24 | $0 | $40.1M |
| Q1 26 | — | $-13.6M | ||
| Q4 25 | — | $-35.8M | ||
| Q3 25 | $-79.1M | $-69.0M | ||
| Q2 25 | $-47.9M | $-25.1M | ||
| Q1 25 | $-70.2M | $-9.4M | ||
| Q4 24 | — | $-32.8M | ||
| Q3 24 | $-82.1M | $-10.2M | ||
| Q2 24 | $-58.3M | $-33.8M |
| Q1 26 | — | -9.3% | ||
| Q4 25 | — | -101.5% | ||
| Q3 25 | -337.9% | -185.8% | ||
| Q2 25 | -292.6% | -67.1% | ||
| Q1 25 | -726.3% | -24.4% | ||
| Q4 24 | — | -85.4% | ||
| Q3 24 | — | -25.9% | ||
| Q2 24 | — | -84.1% |
| Q1 26 | — | -37.4% | ||
| Q4 25 | — | -101.7% | ||
| Q3 25 | -373.3% | -186.0% | ||
| Q2 25 | -229.0% | -67.3% | ||
| Q1 25 | -781.1% | -24.6% | ||
| Q4 24 | — | -85.4% | ||
| Q3 24 | — | -26.1% | ||
| Q2 24 | — | -84.2% |
| Q1 26 | — | $-0.24 | ||
| Q4 25 | — | $-0.63 | ||
| Q3 25 | $-0.30 | $-1.23 | ||
| Q2 25 | $-0.18 | $-0.45 | ||
| Q1 25 | $-0.26 | $-0.17 | ||
| Q4 24 | — | $-0.59 | ||
| Q3 24 | $-0.31 | $-0.18 | ||
| Q2 24 | $-0.22 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $10.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $608.5M |
| Total Assets | $661.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $10.3M | ||
| Q4 25 | — | $22.4M | ||
| Q3 25 | $86.1M | $32.6M | ||
| Q2 25 | $123.8M | $17.4M | ||
| Q1 25 | $95.8M | $9.4M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $657.1M | $16.6M | ||
| Q2 24 | $705.9M | $24.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $465.0M | ||
| Q3 25 | — | $483.0M | ||
| Q2 25 | — | $483.0M | ||
| Q1 25 | — | $505.0M | ||
| Q4 24 | — | $492.0M | ||
| Q3 24 | — | $485.0M | ||
| Q2 24 | — | $462.0M |
| Q1 26 | — | $608.5M | ||
| Q4 25 | — | $623.2M | ||
| Q3 25 | $265.5M | $658.8M | ||
| Q2 25 | $346.5M | $728.0M | ||
| Q1 25 | $371.1M | $753.5M | ||
| Q4 24 | — | $763.9M | ||
| Q3 24 | $477.0M | $800.9M | ||
| Q2 24 | $527.8M | $816.1M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $661.9M | $1.2B | ||
| Q2 25 | $721.0M | $1.3B | ||
| Q1 25 | $746.3M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $827.5M | $1.4B | ||
| Q2 24 | $853.6M | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | 0.73× | ||
| Q2 25 | — | 0.66× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | 0.64× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.57× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | — |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | 51.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $23.6M | ||
| Q3 25 | $-67.9M | $5.7M | ||
| Q2 25 | $-72.8M | $11.6M | ||
| Q1 25 | $-75.6M | $-2.2M | ||
| Q4 24 | — | $54.3M | ||
| Q3 24 | $-76.7M | $13.8M | ||
| Q2 24 | $-51.1M | $17.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 51.4% | ||
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
ONL
| Rental | $36.1M | 100% |
| Fee income from unconsolidated joint venture | $137.0K | 0% |
